NASDAQ: CNSPCns Pharmaceuticals Inc Stock
$0.90+0.08 (+9.76%)
Updated Apr 21, 2025
CNSP Price
$0.90
Fair Value Price
N/A
Market Cap
$2.65M
52 Week Low
$0.77
52 Week High
$800.00
P/E
-0.02x
P/B
0.43x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$14.86M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.41
Operating Cash Flow
-$17M
Beta
0.63
Next Earnings
Apr 30, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CNSP Overview
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CNSP's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CNSP
Ranked#280 of 462
Ranked#280 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important CNSP news, forecast changes, insider trades & much more!
CNSP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CNSP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNSP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CNSP is good value based on its book value relative to its share price (0.43x), compared to the US Biotechnology industry average (4.04x)
P/B vs Industry Valuation
CNSP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CNSP due diligence checks available for Premium users.
Valuation
CNSP fair value
Fair Value of CNSP stock based on Discounted Cash Flow (DCF)
Price
$0.90
Fair Value
$3.29
Undervalued by
72.65%
CNSP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CNSP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.02x
Industry
-184.27x
Market
27.14x
CNSP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.43x
Industry
4.04x
CNSP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CNSP's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.2M
Profit Margin
0%
CNSP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$8.7M
Liabilities
$2.5M
Debt to equity
0.41
CNSP's short-term assets ($8.66M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNSP's short-term assets ($8.66M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNSP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CNSP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.5M
Investing
-$4.2k
Financing
$5.0M
CNSP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CNSP vs Biotech Stocks
Cns Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.